Takahiro Fukuhara

A Randomized Phase 2/3 Study of Ensitrelvir, a Novel Oral SARS-CoV-2 3C-Like Protease Inhibitor, in Japanese Patients with Mild-to-Moderate COVID-19 or Asymptomatic SARS-CoV-2 Infection: Results of the Phase 2a Part

Hiroshi Mukae, Hiroshi Yotsuyanagi, Norio Ohmagari et al. · Antimicrobial Agents and Chemotherapy · 2022 · 136 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +12

Lusutrombopag Reduces Need for Platelet Transfusion in Patients With Thrombocytopenia Undergoing Invasive Procedures

Hisashi Hidaka, Masayuki Kurosaki, Hironori Tanaka et al. · Clinical Gastroenterology and Hepatology · 2018 · 120 citations · Full text

Medicine, Hematology, Surgery +14

A randomized controlled trial of lusutrombopag in Japanese patients with chronic liver disease undergoing radiofrequency ablation

Ryosuke Tateishi, Masataka Seike, Masatoshi Kudo et al. · Journal of Gastroenterology · 2018 · 80 citations · Full text

Medicine, Hematology, Pharmacotherapy +17

Safety, Tolerability, and Pharmacokinetics of the Novel Antiviral Agent Ensitrelvir Fumaric Acid, a SARS-CoV-2 3CL Protease Inhibitor, in Healthy Adults

Ryosuke Shimizu, Takuhiro Sonoyama, Takahiro Fukuhara et al. · Antimicrobial Agents and Chemotherapy · 2022 · 69 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +15

An Encryption-then-Compression system for JPEG 2000 standard

Osamu Watanabe, Akira Uchida, Takahiro Fukuhara et al. · 2015 · 63 citations

Computing, Communication, Computer Science +16